Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 371

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 371
---
 redemptions of Denali Class A Ordinary Shares: (a) 3,712,171 Denali Class A Ordinary Shares redeemed at a per share redemption price of $10.92 in connection with the Extension Meeting that occurred on October 11, 2023 to amend Denali’s amended and restated memorandum and articles of association, (b) 3,785,992 Denali Class A Ordinary Shares redeemed at a per share redemption price of $11.47 in connection with the Second Extension Meeting that occurred on July 10, 2024 to amend Denali’s amended and restated memorandum |

214

| and articles of association, and (c) 708,098 Denali Class A Ordinary Shares redeemed at a per share redemption price of $12.17 in connection with the Third Extension Meeting that occurred on April 11, 2025 to amend Denali’s amended and restated memorandum and articles of association. |

| (2) | The interim redemption scenarios assume the following: |

| Redemption Scenario |     | Number of Denali                 
 Class A Ordinary Shares Redeemed |        |     | Redemption Payments |         |
|:--------------------|:----|:---------------------------------|-------:|:----|:--------------------|--------:|
| 25%                 |     |                                  | 10,935 |     | $                   | 133,079 |
| 50%                 |     |                                  | 21,870 |     | $                   | 266,158 |
| 75%                 |     |                                  | 32,805 |     | $                   | 399,237 |

| (3) | Comprised of 29,117 public shares outstanding as of the date of this proxy statement/prospectus and assumes that the holders of 14,622 Public Units have voluntarily separated such units into their component parts prior to the Closing such that the 14,622 public shares underlying such units are available for redemption in connection with the Business Combination. |

| (4) | Excludes 510,000 Denali Private Placement Units held by the Sponsor. In connection with Denali’s IPO, the Initial Shareholders agreed they would not exercise any redemption rights with respect to the founder shares. In addition, they agreed that they would not transfer, assign or sell their founder shares until the earliest of (a) one year after the completion of Denali’s initial business combination and (b) subsequent to Denali’s initial business combination, (i) if the closing price of the